Solutions for Change

Adamis is focused on saving lives by developing and commercializing treatments for allergy, opioid overdose, respiratory and inflammatory diseases.

 ZIMHI technology – watch our video that explains its mechanism of action

About Us

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease.

The Company’s SYMJEPI® (epinephrine) Injection is approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The Company’s ZIMHI® (naloxone) Injection is approved for the treatment of opioid overdose. Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial has been conducted.

Areas of Focus: Allergy, Respiratory and Opioid overdose

SYMJEPI® (epinephrine)
ZIMHI® (naloxone)
APC-400 (tempol) – Capsule

Our Latest News Releases